A detailed history of Colonial Trust Advisors transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Colonial Trust Advisors holds 50 shares of REGN stock, worth $30,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50
Previous 50 -0.0%
Holding current value
$30,000
Previous $31,000 16.13%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 13, 2025

BUY
$634.14 - $744.83 $31,707 - $37,241
50 New
50 $31,000
Q1 2024

May 13, 2024

SELL
$902.69 - $993.35 $4,513 - $4,966
-5 Reduced 55.56%
4 $3,000
Q4 2023

Feb 14, 2024

BUY
$775.18 - $881.7 $2,325 - $2,645
3 Added 50.0%
9 $7,000
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $4,235 - $4,598
6 New
6 $4,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $64.3B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Colonial Trust Advisors Portfolio

Follow Colonial Trust Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Colonial Trust Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Colonial Trust Advisors with notifications on news.